| CAS NO: | 129024-87-9 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 129024-87-9 |
| Canonical SMILES | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(NCCC1=CC=C(O)C(O)=C1)=O |
| 分子式 | C30H41NO3 |
| 分子量 | 463.65 |
| 溶解度 | DMSO: ≥ 100 mg/mL (215.68 mM); Ethanol: 100 mg/mL (215.68 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine. NMI 8739 is a dopamine D2 autoreceptor agonist[1], which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine[2]. NMI 8739 reduces nitric oxide (NO) production in LPS-stimulated RAW264.7 Macrophages. NMI 8739 elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 Release in RAW264.7 macrophages after LPS-stimulation. Production of PGE2 is concentration-dependently suppressed with a reduction of 25.3% at 100 nM NMI 8739 and a 75% reduction for 1 μM NMI 8739. 2 μM NMI 8739 significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectively[3]. [1]. Gill Higgins, New drugs signal rapid growth of anti-obesity drug market. RESEARCH & DEVELOPMENT. 2 Nov 11K16 No. 1061 [2]. Shashoua VE, et al. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci. 1996;58(16):1347-57. [3]. Wang Y, et al. N-Docosahexaenoyl Dopamine, an Endocannabinoid-like Conjugate of Dopamine and the n-3 Fatty Acid Docosahexaenoic Acid, Attenuates Lipopolysaccharide-Induced Activation of Microglia and Macrophages via COX-2. ACS Chem Neurosci. 2017 Mar 15;8(3):548-557. |
m.cnreagent.com